Disease · EFO_0003896
left ventricular hypertrophy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. left ventricular hypertrophy. Diseases, record EFO_0003896. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003896
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Hypertrophies, Left Ventricular, Hypertrophy, Left Ventricular, Left Ventricular Hypertrophies, Ventricular Hypertrophies, Left, Ventricular Hypertrophy, Left
- Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LOSARTAN | CHEMBL191 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ATENOLOL | CHEMBL24 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| VALSARTAN | CHEMBL1069 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PARICALCITOL | CHEMBL1200622 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IRBESARTAN | CHEMBL1513 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LISINOPRIL ANHYDROUS | CHEMBL1237 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AGALSIDASE ALFA | CHEMBL2108214 | Enzyme | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALISKIREN | CHEMBL1639 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANDESARTAN | CHEMBL1016 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets25
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 5 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 2 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADRB1 | Adrenergic receptor beta | 2 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| SLC12A3 | Solute carrier family 12 member 3 | 2 | Thiazide-sensitive sodium-chloride cotransporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6559 | Drugs and targets |
| VDR | Vitamin D3 receptor | 2 | Vitamin D receptor agonist | Phase 3 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Phase 3 | https://conductscience.org/library/genes/155 | Drugs and targets |
1 to 10 of 25
See all 25 targetsTrials25
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00219141 | Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension | Phase 3 | 460 | 2011-05-10 | Hypertension, Left Ventricular Hypertrophy, Overweight | ALISKIREN, LOSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00108082 | The CLEVER Study - Coreg And Left Ventricular Mass Regression | Phase 3 | 287 | 2009-11-09 | Hypertrophy, Left Ventricular | ATENOLOL, CARVEDILOL, LISINOPRIL ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00497146 | The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 | Phase 3 | 227 | 2011-12-23 | Chronic Kidney Disease, Left Ventricular Hypertrophy | PARICALCITOL | Its record names the disease | ClinicalTrials.gov |
| NCT00582114 | Hypertension in Hemodialysis Patients (Aim 3) | Phase 3 | 200 | 2016-01-18 | Hemodialysis, Hypertension, Left Ventricular Hypertrophy | ATENOLOL, LISINOPRIL ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00389168 | Irbesartan and Atenolol in Hypertensive Heart Disease | Phase 2/3 | 115 | 2015-05-05 | Hypertension | ATENOLOL, IRBESARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00446563 | Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy | Phase 3 | 90 | 2011-04-27 | Hypertension; Hypertrophy, Left Ventricular | AMLODIPINE, HYDROCHLOROTHIAZIDE, LOSARTAN, VALSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00864851 | Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease | Phase 3 | 44 | 2014-06-06 | Fabry Disease | AGALSIDASE ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01150461 | Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy | Phase 2 | 20 | 2013-09-05 | Hypertrophic Cardiomyopathy | LOSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00616902 | The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 | Phase 3 | 12 | 2010-08-04 | Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | PARICALCITOL | Its record names the disease | ClinicalTrials.gov |
| NCT00338260 | Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) | Phase 3 | 496 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | ATENOLOL, LOSARTAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 25
See all 25 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Atenolol vs Lisinopril: serious adverse events | 58 of 100 | 70 of 100 | 200 | NCT00582114 | Trial comparisons |
| Atenolol vs Irbesartan: Number of Participants With Serious Adverse Events | 5 of 58 | 5 of 56 | 114 | NCT00389168 | Trial comparisons |
| Irbesratan vs Atenolol: serious adverse events | 5 of 56 | 5 of 58 | 114 | NCT00389168 | Trial comparisons |
| Valsartan and Amlodipine vs Losartan and HCTZ: serious adverse events | 2 of 43 | 6 of 47 | 90 | NCT00446563 | Trial comparisons |
| Losartan 50 PO mg BID vs Placebo: serious adverse events | 0 of 11 | 0 of 9 | 20 | NCT01150461 | Trial comparisons |
| Paricalcitol Injection 4 Mcg/mL vs Placebo Injection 4 Mcg/mL: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT00616902 | Trial comparisons |
Papers from its trials68
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0003896
GET https://conductscience.org/api/diseases/v1/EFO_0003896/drugs?page=2